Table 2.
Baseline characteristics of patients in the POOLED cohort with established CVD, with stratification by the number of life-years free of new/recurrent CVD events gained by adding semaglutide to SoC
| Life-years free of new/recurrent CVD events gained | |||||
|---|---|---|---|---|---|
| 0 to <1 | 1 to <2 | 2 to <3 | 3 to <4 | 4 to <5 | |
| N | 307 | 2,031 | 2,028 | 334 | 20 |
| Age, years | 78.5 (4.1) | 69.2 (4.7) | 60.0 (4.8) | 56.3 (3.4) | 51.9 (1.2) |
| Sex, female, n (%) | 40.0 (13.0) | 431.0 (21.2) | 617.0 (30.4) | 323.0 (96.7) | 20.0 (100.0) |
| Diabetes duration, years | 20.5 (10.6) | 16.1 (8.6) | 12.0 (7.0) | 10.6 (6.8) | 10.1 (7.9) |
| Current smoker, n (%) | 24.0 (7.8) | 263.0 (12.9) | 287.0 (14.2) | 30.0 (9.0) | 0.0 (0) |
| BMI, kg/m2 | 30.9 (6.8) | 32.3 (6.4) | 32.5 (6.0) | 33.5 (5.8) | 33.8 (4.8) |
| HbA1c, mmol/mol | 66 (13) | 67 (16) | 69 (18) | 73 (19) | 71 (16) |
| HbA1c, % | 8.2 (1.2) | 8.3 (1.5) | 8.5 (1.6) | 8.8 (1.7) | 8.6 (1.5) |
| SBP, mmHg | 137.5 (20.8) | 136.3 (17.6) | 133.5 (16.2) | 132.5 (15.6) | 134.3 (12.2) |
| DBP, mmHg | 72.4 (10.6) | 75.0 (10.2) | 77.9 (9.8) | 78.7 (9.7) | 79.6 (9.5) |
| Total cholesterol, mmol/L, geometric mean (CoV) | 3.92 (24.50) | 3.94 (26.66) | 4.10 (28.60) | 4.61 (29.92) | 4.81 (28.32) |
| LDL cholesterol, mmol/L | 2.10 (0.74) | 2.10 (0.86) | 2.24 (0.93) | 2.59 (1.13) | 2.91 (1.26) |
| Non-HDL cholesterol, mmol/L | 2.91 (0.96) | 2.97 (1.05) | 3.16 (1.16) | 3.58 (1.40) | 3.77 (1.40) |
| Triglycerides, mmol/L | 1.80 (1.08) | 1.99 (1.49) | 2.15 (1.73) | 2.30 (1.86) | 1.90 (0.74) |
| eGFR, mL/min/1.73 m2* | 49.8 (16.8) | 69.3 (19.6) | 85.9 (17.1) | 95.3 (13.2) | 102.8 (9.1) |
Data are means (SD) unless otherwise indicated. CoV, coefficient of variation; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
*
Estimated using the CKD-EPI creatinine equation.